Cargando…
Cost Drivers of a Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia Phase 3 Clinical Trial
BACKGROUND: Studies indicate that the prevalence of multidrug-resistant infections, including hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), has been rising. There are many challenges associated with these disease conditions and the ability to develo...
Autores principales: | Stergiopoulos, Stella, Calvert, Sara B, Brown, Carrie A, Awatin, Josephine, Tenaerts, Pamela, Holland, Thomas L, DiMasi, Joseph A, Getz, Kenneth A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5848330/ https://www.ncbi.nlm.nih.gov/pubmed/29020279 http://dx.doi.org/10.1093/cid/cix726 |
Ejemplares similares
-
Cost Effectiveness of Ceftolozane/Tazobactam Compared with Meropenem for the Treatment of Patients with Ventilated Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia
por: Naik, Jaesh, et al.
Publicado: (2021) -
EE388 Cost Effectiveness of Novel Antibiotic Ceftolozane/Tazobactam in Patients With Hospital-Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia in Greece
por: Yfantopoulos, N, et al.
Publicado: (2022) -
Cost–effectiveness of imipenem/cilastatin/relebactam for hospital-acquired and ventilator-associated bacterial pneumonia
por: Naik, Jaesh, et al.
Publicado: (2023) -
Community-Acquired Pneumonia, Bacterial
por: File, Thomas M.
Publicado: (2012) -
Assessing the Financial Value of Decentralized Clinical Trials
por: DiMasi, Joseph A., et al.
Publicado: (2022)